Applied Biosystems and Eppendorf Announce Licensing Agreement
News Nov 14, 2005
Under the agreement, Eppendorf will have the right to manufacture and sell real-time thermal cyclers in the research and applied fields.
"This agreement with Eppendorf further validates the significance of Applied Biosystems' real-time thermal cycler technology," said Paul D. Grossman, Ph.D., Esq., Vice President, Strategic Planning, Business Development and Intellectual Property for Applied Biosystems.
"We may consider entering into additional licenses with high quality vendors under the right terms."
"We are pleased to announce our agreement with Applied Biosystems," said Klaus Fink, CEO and President of Eppendorf AG.
"We are committed to providing our customers with access to technologies that are of greatest importance for the life sciences sector."
"Our new product generation of real-time cyclers ensures best practices in laboratories in terms of productivity, simplicity, and ease of use."
The license to Eppendorf is based on U.S. Patent No. 6,814,934 and foreign equivalents.
The U.S. Patent & Trademark Office (USPTO) granted Applera this fundamental patent pertaining to real-time PCR instrumentation in November 2004.
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE